Literature DB >> 26436556

Emerging treatments for recurrent prostate cancer.

Catherine Hanna1, Robert J Jones2.   

Abstract

Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease. We consider salvage treatments aimed at those with local recurrence confined to the prostate gland, therapies for those presenting with metastatic recurrence and the approach to men presenting with a rising prostate-specific antigen but no demonstrable disease (M0). In general, men with recurrent disease are often under-represented in randomized clinical trials. Consequently, evidence to guide treatment for these men is often lacking and this needs to be addressed in order to improve and better define our approach to this problem in the future.

Entities:  

Keywords:  cancer; cryotherapy; docetaxel; immunotherapy; prostate; prostatectomy; radiotherapy; recurrent; relapse; salvage

Mesh:

Year:  2015        PMID: 26436556     DOI: 10.2217/fon.15.228

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  MicroRNA-30a functions as tumor suppressor and inhibits the proliferation and invasion of prostate cancer cells by down-regulation of SIX1.

Authors:  Qinghuan Zhu; Hongzhi Li; Yingjie Li; Lining Jiang
Journal:  Hum Cell       Date:  2017-06-01       Impact factor: 4.174

2.  MicroRNA-212 Targets Mitogen-Activated Protein Kinase 1 to Inhibit Proliferation and Invasion of Prostate Cancer Cells.

Authors:  Bo Hu; Xunbo Jin; Jianbo Wang
Journal:  Oncol Res       Date:  2018-01-10       Impact factor: 5.574

3.  LINC00689 promotes prostate cancer progression via regulating miR-496/CTNNB1 to activate Wnt pathway.

Authors:  Liwei Meng; Zhonghai Li; Ye Chen; Deqian Liu; Zhaoxu Liu
Journal:  Cancer Cell Int       Date:  2020-06-05       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.